Form 4: Medtronic SVP Receives Substantial Future Equity Compensation Grants

Medtronic plc's Senior Vice President and Chief HR Officer, Matthew R. Walter, was granted significant equity awards including restricted stock units, performance share units, and stock options, effective July 28, 2025.

Summary

• Matthew R. Walter, SVP, Chief HR Officer of Medtronic plc, was granted equity awards on July 28, 2025.
• The grants include 4,350 Ordinary Shares as Restricted Stock Units (RSUs), which vest 100% on the third anniversary of the grant date (July 28, 2028).
• An additional 10,874 Performance Share Units (PSUs) were granted, representing a contingent right to receive Medtronic common stock, with performance conditions expected to be satisfied by April 28, 2028.
• The number of shares issued from PSUs can range from 0 to 21,748, depending on the achievement of specific performance metrics over a three-year period, with 10,874 shares issued if target performance is met.
• Also granted were 30,669 Stock Options with an exercise price of $91.97, which become exercisable at a rate of 25% per year starting on the first anniversary of the grant (July 28, 2026) and expire on July 28, 2035.
• Following these transactions, Matthew R. Walter beneficially owns 30,625 Ordinary Shares, which includes 99 shares acquired through dividend reinvestment and 122 shares acquired under Medtronic's Employee Stock Ownership Plan since the last report.
• The reporting person also beneficially owns 10,874 Performance Share Units and 30,669 Stock Options.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation grants to a senior executive, which is a positive for aligning management incentives with long-term shareholder value. It does not indicate any negative operational or financial news for the company.

Positives

• The grants of restricted stock units, performance share units, and stock options align the executive's long-term interests with those of Medtronic plc shareholders.
• Equity compensation is a standard practice that incentivizes executives to drive company performance and shareholder value.
• The potential for significant share issuance from performance share units (up to 21,748 shares) provides a strong incentive for achieving high performance metrics.

Negatives

• The value of the performance share units is contingent on meeting specific performance metrics, meaning the executive may receive fewer or no shares if minimum performance is not met.
• The stock options' value is dependent on Medtronic's share price exceeding the exercise price of $91.97, introducing market risk.

Risks

• Performance conditions for the Performance Share Units may not be fully satisfied, leading to a lower number of shares vesting or no shares at all.
• The market price of Medtronic plc's ordinary shares could decline below the stock option exercise price, rendering the options underwater and valueless.
• Future market volatility could impact the ultimate value of all equity awards upon vesting or exercise.

Future Outlook

The future outlook for these equity awards is tied to Medtronic plc's performance over the next three years, which will determine the final number of shares issued from Performance Share Units, and the company's stock price performance relative to the stock option exercise price.

Industry Context

The granting of equity compensation, including restricted stock units, performance share units, and stock options, is a common and widely accepted practice in the medical technology and broader corporate sectors for executive remuneration. It serves to align the interests of senior management with long-term shareholder value creation.

Comparison to Industry Standards

• The structure of equity grants, combining RSUs, PSUs, and stock options, is consistent with typical executive compensation packages observed across large-cap companies in the healthcare and technology sectors, such as Johnson & Johnson, Abbott Laboratories, and Stryker Corporation.
• The vesting schedules (e.g., 3-year cliff for RSUs, 3-year performance period for PSUs, annual vesting for options) are standard for long-term incentive plans designed to retain talent and incentivize sustained performance.
• The use of performance-based units (PSUs) is a best practice in corporate governance, linking executive pay directly to the achievement of strategic and financial objectives, similar to programs at peer companies.

Related Party Transactions

• Grants of equity compensation (restricted stock units, performance share units, and stock options) to Matthew R. Walter, a senior officer of Medtronic plc, constitute a related party transaction as part of his executive remuneration package.

Stakeholder Impact

• Shareholders: The grants aim to align the executive's interests with shareholder value creation, potentially leading to improved long-term company performance.
• Employees: While not directly impacting all employees, executive compensation practices can influence overall company culture and compensation philosophy.

Next Steps

• Monitoring the vesting of Restricted Stock Units on July 28, 2028.
• Assessing the achievement of performance metrics for Performance Share Units by April 28, 2028, to determine the final number of shares to be issued.
• Observing the exercisability of Stock Options beginning July 28, 2026, and their expiration on July 28, 2035.

Key Dates

Recommendation

This Form 4 reports routine equity compensation grants to a senior executive, which is a standard practice to align management incentives with shareholder interests. It does not contain information that would warrant a change in investment thesis for Medtronic plc, nor does it provide new financial or operational data to alter a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate as this filing is a standard disclosure of executive compensation.

Keywords

Medtronic, MDT, SEC Form 4, Equity Compensation, Restricted Stock Units, Performance Share Units, Stock Options, Executive Compensation, Beneficial Ownership, Insider Transaction